Leerink Partners analyst Danielle Antalffy maintained a Buy rating on Nevro Crop (NYSE:NVRO) on Monday, setting a price target of $175, which is approximately 16.61% above the present share price of $150.07.
Antalffy expects Nevro Crop to post earnings per share (EPS) of -$1.21 for the fourth quarter of 2020.
The current consensus among 10 TipRanks analysts is for a Strong Buy rating of shares in Nevro Crop, with an average price target of $154.44.
The analysts price targets range from a high of $175 to a low of $139.
In its latest earnings report, released on 06/30/2020, the company reported a quarterly revenue of $56.39 million and a net profit of -$35.36 million. The company's market cap is $5.15 billion.
According to TipRanks.com, Leerink Partners analyst Danielle Antalffy is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 20.6% and a 65.90% success rate.
Nevro Corp . engages in the provision of medical devices. The firm focuses on providing products that improve the quality of life of patients suffering from debilitating chronic pain. It develops and commercializes senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company was founded by Konstantinos Alataris in March 2006 and is headquartered in Redwood (NYSE:RWT) City, CA.